X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will focus on the R&D and commercialization of proprietary science and technologies for therapeutics, including Entadfi, a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a PDE5 inhibitor.
Lead Product(s): Finasteride,Tadalafil
Therapeutic Area: Urology Product Name: Entadfi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Onconetix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 18, 2023
Details:
Preliminary preclinical data supporting the use of its norovirus shell and protrusion (“S&P”) virus-like particle (“VLP”) platform to develop a novel monkeypox vaccine candidate.
Lead Product(s): VLP Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
Under the collaboration, Blue Water Biotech and IQVIA will market Blue Water’s commercial portfolio including, Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for benign prostatic hyperplasia and Zontivity (vorapaxar).
Lead Product(s): Finasteride,Tadalafil
Therapeutic Area: Urology Product Name: Entadfi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: IQVIA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 21, 2023
Details:
Blue Water expands its commercial portfolio by purchasing six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain management. The assets also include Conjupri (levamlodipine), a calcium channel blocker for the hypertension.
Lead Product(s): Levoamlodipine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Conjupri
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: WraSer Pharmaceuticals
Deal Size: $8.5 million Upfront Cash: $8.5 million
Deal Type: Acquisition June 14, 2023
Details:
The acquisition transforms the Company into a broader pharmaceutical company spanning multiple sectors by including ENTADFI (finasteride), an oral, once daily treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a PDE5 inhibitor.
Lead Product(s): Finasteride,Tadalafil
Therapeutic Area: Urology Product Name: Entadfi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Veru
Deal Size: $100.0 million Upfront Cash: $20.0 million
Deal Type: Agreement April 20, 2023
Details:
Under the agreement, BWV will fund the NHP study to further evaluate the efficacy of BWV-401, a live attenuated, orally delivered Chlamydia vaccine, and provide additional support for development towards human clinical trials.
Lead Product(s): BWV-401
Therapeutic Area: Infections and Infectious Diseases Product Name: BWV-401
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: University of Texas Health Science Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 12, 2023
Details:
Blue Water Vaccines and AbVacc will collaborate for the joint development of vaccine candidates targeting monkeypox and Marburg virus disease. Both candidate vaccines will utilize BWV’s norovirus shell and protrusion VLP platform.
Lead Product(s): Monkeypox Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: AbVacc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 01, 2023
Details:
Chlamydia vaccines have historically been challenging to produce, but the novel approach has demonstrated strong results in mouse models, which will translate into a human vaccine candidate.
Lead Product(s): Live Attenuated Chlamydia Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: University of Texas Health San Antonio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 21, 2022
Details:
New data, based on experiments at St. Jude Children’s Research Hospital, suggests that BWV-201 may also provide protection against pneumococcal pneumonia by limiting the ability of Streptococcus pneumoniae to infect the lungs.
Lead Product(s): BWV-201
Therapeutic Area: Infections and Infectious Diseases Product Name: BWV-201
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
The Company intends to use the net proceeds from the private placement for the research and development of its pipeline as well as for working capital and other general corporate purposes.
Lead Product(s): BWV-101
Therapeutic Area: Infections and Infectious Diseases Product Name: BWV-101
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
